Long-term depot medroxyprogesterone acetate (Depo-Provera) use in inner-city adolescents.
To determine Depo-Provera continuation rates and reasons for its discontinuation among adolescents.
Medical record reviews and telephone interviews with 159 adolescents who initiated Depo-Provera use between 1 December 1992 and 31 December 1995 at two clinics in New York City.
Depo-Provera continuation was measured using lifetable analysis.
The mean age was 17.7 ± 1.5 years, with a median of 1 pregnancy (range 0-11).
Mean follow-up was 23.4 ± 10.7 months.
Depo-Provera continuation rates were 71% at 3 months, 48% at 6 months, and 27% at 12 months, and were not affected by age, race, pregnancy or contraceptive history, clinic, or foster care status.
Forty-three subjects (37% of discontinuers) restarted Depo-Provera during the study period, with a mean time to restart of 8.4 months after the last Depo-Provera injection.
Side effects were the main reported reason for Depo-Provera discontinuation, primarily menstrual irregularities (26%) and weight gain (18%). Seventy percent of those discontinuing Depo-Provera owing to irregular bleeding did so after only one injection.
For 23%, the single reason for discontinuation was appointment noncompliance.
Restart rates were lowest among those who reported irregular bleeding (15%), weight gain (9%), and hair loss (10%), and highest among those discontinuing owing to missed appointments (87%) (p<0.05).
Pregnancies occurred in 19% of Depo-Provera discontinuers. (...)
Mots-clés Pascal : Prévention, Gestation, Contraception, Médroxyprogestérone, Contraceptif, Forme libération contrôlée, Observance thérapeutique, Long terme, Adolescent, Homme, Femelle
Mots-clés Pascal anglais : Prevention, Pregnancy, Contraception, Medroxyprogesterone, Contraceptive, Controlled release form, Treatment compliance, Long term, Adolescent, Human, Female
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 98-0450005
Code Inist : 002B20A01. Création : 25/01/1999.